THE APEX TIMES
CMS Administrator Mehmet Oz tells senators to reject Sen. Ted Budd hemp amendment
In a Friday letter, Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz urged lawmakers to oppose an amendment sponsored by Sen. Ted Budd that would, according to Oz, pave the way for a federal ban on most hemp-derived products to take effect in November.
Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz urged senators to reject an amendment offered by Sen. Ted Budd (R-N.C.) that would change federal authority over hemp-derived products, warning that it would trigger a broad federal ban beginning in November, according to a Friday letter reported by The Hill.
Oz, who leads CMS, said he had “grave concerns” about the amendment. The letter’s core issue, as described in the report, is the amendment’s effect timing and the scope of products that would be covered if the ban is allowed to take effect in November.
The Budd amendment is described as part of a wider spending package, where amendments are often paired with procedural and timing decisions about how government funding is finalized. Oz’s intervention adds to the executive-branch pressure lawmakers face as they weigh whether to adopt changes that would alter regulatory expectations for the hemp market.
Under the amendment as characterized in the reporting, a federal ban on most hemp-derived products would be set to begin in November. The practical effect, if adopted, would be a shift in compliance and enforcement expectations for producers and sellers of hemp-derived items, raising the stakes for businesses that would have to adjust or halt sales ahead of the effective date.
Oz’s letter also frames the proposal as a decision for Congress, urging senators not to support it. The report indicates Oz’s opposition is based on concerns about the amendment’s approach rather than on the substance of a standalone regulatory proposal issued by an agency.
It is not clear from the available report how senators will treat the amendment during final floor negotiations, or whether the amendment text is expected to advance unchanged. Additional procedural and statutory details would be required to determine which specific products would be affected and which enforcement entities would implement the November timeline.
Why It Matters
- If enacted as described, the November effective date would create a near-term compliance and enforcement shift for hemp-derived products.
- Because the proposal is embedded in a spending bill process, its fate may depend on amendment negotiations rather than a standalone regulatory pathway.
- Oz’s role as the CMS administrator indicates the executive branch is seeking to influence Congress’s legislative text before final passage and implementation.
- The scope of “most hemp-derived products” and the specific statutory mechanisms would determine how enforcement works and how quickly affected businesses and regulators would need to adjust.
Key Facts
- CMS Administrator Dr. Mehmet Oz sent a Friday letter urging senators to reject a hemp-related amendment.
- The amendment was offered by Sen. Ted Budd (R-N.C.).
- The letter said Oz has “grave concerns” about the amendment.
- The report describes the amendment as allowing a federal ban on most hemp-derived products to take effect in November.
- The amendment is described as connected to a broader spending bill package.